AU2012224954C1 - Semisolid aqueous pharmaceutical composition containing tapentadol - Google Patents

Semisolid aqueous pharmaceutical composition containing tapentadol Download PDF

Info

Publication number
AU2012224954C1
AU2012224954C1 AU2012224954A AU2012224954A AU2012224954C1 AU 2012224954 C1 AU2012224954 C1 AU 2012224954C1 AU 2012224954 A AU2012224954 A AU 2012224954A AU 2012224954 A AU2012224954 A AU 2012224954A AU 2012224954 C1 AU2012224954 C1 AU 2012224954C1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
tapentadol
composition according
composition
still
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012224954A
Other languages
English (en)
Other versions
AU2012224954B2 (en
AU2012224954A1 (en
Inventor
Roger Carolus Augusta Embrechts
Sabine Karine Katrien Inghelbrecht
Ulrich Reinhold
Marc Schiller
Eva WULSTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2012224954A1 publication Critical patent/AU2012224954A1/en
Publication of AU2012224954B2 publication Critical patent/AU2012224954B2/en
Priority to AU2017200040A priority Critical patent/AU2017200040B2/en
Application granted granted Critical
Publication of AU2012224954C1 publication Critical patent/AU2012224954C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2012224954A 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol Ceased AU2012224954C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017200040A AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449,329 2011-03-04
EP11003603.5 2011-05-03
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017200040A Division AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Publications (3)

Publication Number Publication Date
AU2012224954A1 AU2012224954A1 (en) 2013-09-19
AU2012224954B2 AU2012224954B2 (en) 2016-10-20
AU2012224954C1 true AU2012224954C1 (en) 2017-04-06

Family

ID=44652117

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012224954A Ceased AU2012224954C1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol
AU2017200040A Ceased AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017200040A Ceased AU2017200040B2 (en) 2011-03-04 2017-01-04 Semisolid aqueous pharmaceutical composition containing tapentadol

Country Status (24)

Country Link
US (3) US9446008B2 (enExample)
EP (3) EP3766489B1 (enExample)
JP (3) JP6027549B2 (enExample)
KR (2) KR102039320B1 (enExample)
CN (1) CN103501774A (enExample)
AU (2) AU2012224954C1 (enExample)
BR (1) BR112013022556A8 (enExample)
CA (1) CA2828637C (enExample)
CY (1) CY1119725T1 (enExample)
DK (1) DK2680834T3 (enExample)
EA (2) EA025194B1 (enExample)
ES (2) ES2910085T3 (enExample)
HR (1) HRP20171836T1 (enExample)
HU (1) HUE037491T2 (enExample)
IL (2) IL227826B (enExample)
LT (1) LT2680834T (enExample)
MX (2) MX374468B (enExample)
NO (1) NO2680834T3 (enExample)
PL (1) PL2680834T3 (enExample)
PT (2) PT3766489T (enExample)
RS (1) RS56692B1 (enExample)
SI (1) SI2680834T1 (enExample)
WO (1) WO2012119729A1 (enExample)
ZA (1) ZA201306480B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
NO2680834T3 (enExample) 2011-05-03 2018-03-17
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
ES2710299T3 (es) 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
ES3027562T3 (en) * 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
EP3826631A1 (en) * 2018-07-24 2021-06-02 Dr. August Wolff GmbH & Co. KG Arzneimittel Topical emulsion of an anticholinergic compound
MX2021011355A (es) 2019-03-18 2021-10-13 Sunstar Americas Inc Composicion para cuidado oral.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
PL223471B1 (pl) 2002-03-15 2016-10-31 Cypress Bioscience Inc Kompozycja farmaceutyczna zawierająca milnacypran do stosowania w leczeniu zespołu nadwrażliwości jelita grubego
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
WO2004024126A1 (en) 2002-09-13 2004-03-25 Cydex, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
DE602004007905T2 (de) 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
JP5700904B2 (ja) 2004-07-01 2015-04-15 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング （１ｒ，２ｒ）−３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノールを含有する乱用防止経口投与形態物
CA2606947A1 (en) 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US20080039405A1 (en) * 2006-04-25 2008-02-14 Croda, Inc. Modification of percutaneous absorption of topically active materials
EP2012764B1 (en) 2006-04-28 2011-01-12 Grünenthal GmbH Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
PT2012763E (pt) 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
CA2656696C (en) 2006-07-24 2013-06-11 Janssen Pharmaceutica N.V. Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101607112B1 (ko) * 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
ES2758831T3 (es) * 2008-10-30 2020-05-06 Gruenenthal Gmbh Nuevas y potentes formas de dosificación de tapentadol
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20110190267A1 (en) * 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
EP2552486B1 (en) * 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
NO2680834T3 (enExample) 2011-05-03 2018-03-17

Also Published As

Publication number Publication date
AU2012224954B2 (en) 2016-10-20
HUE037491T2 (hu) 2018-09-28
JP2014506900A (ja) 2014-03-20
CA2828637C (en) 2019-06-11
KR102039320B1 (ko) 2019-11-01
JP6259042B2 (ja) 2018-01-10
EA025194B1 (ru) 2016-11-30
PT3766489T (pt) 2022-04-07
BR112013022556A2 (pt) 2016-12-06
AU2017200040B2 (en) 2018-09-06
US20120225950A1 (en) 2012-09-06
MX374468B (es) 2025-03-06
EA201300988A1 (ru) 2014-06-30
JP2018065839A (ja) 2018-04-26
RS56692B1 (sr) 2018-03-30
CA2828637A1 (en) 2012-09-13
AU2012224954A1 (en) 2013-09-19
EA033171B1 (ru) 2019-09-30
WO2012119729A1 (en) 2012-09-13
EP2680834B1 (en) 2017-10-18
EP2680834A1 (en) 2014-01-08
AU2017200040A1 (en) 2017-02-02
KR101911362B1 (ko) 2018-10-25
BR112013022556A8 (pt) 2018-01-16
JP2017039756A (ja) 2017-02-23
PT2680834T (pt) 2018-01-25
DK2680834T3 (en) 2017-12-04
KR20180116463A (ko) 2018-10-24
SI2680834T1 (en) 2018-01-31
CY1119725T1 (el) 2018-06-27
ES2910085T3 (es) 2022-05-11
CN103501774A (zh) 2014-01-08
IL227826B (en) 2018-04-30
EP3290029A1 (en) 2018-03-07
ZA201306480B (en) 2014-05-28
MX344473B (es) 2016-12-16
IL258357A (en) 2018-05-31
EA201600442A1 (ru) 2017-02-28
US9446008B2 (en) 2016-09-20
IL227826A0 (en) 2013-09-30
KR20140013020A (ko) 2014-02-04
NO2680834T3 (enExample) 2018-03-17
MX2013010100A (es) 2013-10-01
US20160346229A1 (en) 2016-12-01
HRP20171836T1 (hr) 2017-12-29
ES2654407T3 (es) 2018-02-13
JP6027549B2 (ja) 2016-11-16
PL2680834T3 (pl) 2018-03-30
LT2680834T (lt) 2018-01-10
US20180133174A1 (en) 2018-05-17
JP6670283B2 (ja) 2020-03-18
EP3766489B1 (en) 2022-03-16
EP3290029B1 (en) 2020-09-02
EP3766489A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
AU2012224954C1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
AU2012224952B2 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
JP2025085814A (ja) 医薬組成物
HK1250664A1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966A (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1194966B (en) Semisolid aqueous pharmaceutical composition containing tapentadol
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
US20190388364A1 (en) Tapentadol as a local anesthetic
JP2014208617A (ja) 医薬組成物
TW201832765A (zh) 膀胱內投藥用於治療膀胱痛之組合物
JP2024519493A (ja) 局所ナプロキセン製剤及びそれらの使用
JP2017178843A (ja) 乳化組成物

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 DEC 2016

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 DEC 2016

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired